

China Biologic Products, Inc.
Form 8-K
March 07, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest event Reported): March 7, 2011

CHINA BIOLOGIC PRODUCTS, INC.
(Exact name of registrant as specified in its charter)

Delaware
*(State or other jurisdiction of
incorporation or organization)*

001-34566
(Commission File No.)

75-2308816
(IRS Employer ID No.)

**No. 14 East Hushan Road,
Tai'an City, Shandong, 271000
People's Republic of China**
(Address of Principal Executive Offices)

86-538 -620-2306
Registrant's telephone number, including area code

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
-

Item 7.01 Regulation FD Disclosure.

In connection with the distribution of presentation materials by China Biologic Products, Inc. (the "Company") at the Annual China Investment Conference held by Rodman & Renshaw (the "Rodman Conference") and in anticipation of the planned presentations at the Rodman Conference and the 31st Annual Healthcare Conference held by Cowen and Company, LLC (the "Cowen Conference," and together with the Rodman Conference, the "Conferences") and the distribution of materials at the Cowen Conference, the Company is furnishing the information contained in this current report on Form 8-K in order to avoid the selective disclosure of any material nonpublic information at the Conferences. The Company's presentation materials are attached hereto as Exhibits 99.1.

The information contained in this Current Report on Form 8-K and the exhibits attached hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information or such exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in or exhibits to this Form 8-K shall not be deemed an admission as to the materiality of any information in this report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
<u>99.1</u>	<u>Presentation of the Company, March 2011</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 7, 2011

CHINA BIOLOGIC PRODUCTS, INC.

By: /s/ Chao Ming Zhao

Chao Ming Zhao

Chief Executive Officer

EXHIBIT INDEX

Exhibit No.	Description
<u>99.1</u>	<u>Presentation of the Company, March 2011</u>

4
